In addition, it is beneficial for the mAb to possess intrinsic anti-tumour activity resulting from either direct modulation of the biological activity of the target antigen (e.g., anti-HER2 mAbs) [80] and/or via immune effector functions such as ADCC, CDC and CDCC [81]. Here, ERBB2 is linked to neoplasm.